“…terminal synthase, which is usually coupled with COX-2 to mediate the production of PGE2 in inflammatory states (Deng et al, 2019;Thoren & Jakobsson, 2000;Uematsu, Matsumoto, Takeda, & Akira, 2002), has gained considerable attention as a preferable target for new generation of antipyretic and analgesic drugs (Bergqvist, Morgenstern, & Jakobsson, 2019;Yang & Chen, 2016). It has been reported that, unlike COX-2 selective inhibitors, deletion of mPGES-1 in mice is protective to inflammatory vascular diseases, for example, retards atherogenesis (Wang et al, 2006), suppresses abdominal aortic aneurysm formation (Wang et al, 2008a), limits post-injury neointima hyperplasia (Wang et al, 2011).…”